Conference Coverage

VIDEO: HER2+ patients may do fine with local therapies alone


 

AT MBCC

– Unquestionably, the advent of human epidermal growth factor receptor-2 (HER2) inhibitors has dramatically improved long-term outcomes in patients with HER2-positive breast cancer.

But the benefits of therapy with the HER2-inhibitor trastuzumab (Herceptin) must be weighed against its potential for causing or exacerbating cardiomyopathy, especially when combined with anthracyclines such as doxorubicin that are associated with increased risk for late cardiotoxicity, said Sara Hurvitz, MD, director of the Breast Cancer Clinical Research Program at the David Geffen School of Medicine at UCLA in Santa Monica, Calif.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Many patients with HER2-positive disease can be safely and effectively treated with local therapy alone, but clinicians at present have no reliable way of knowing which patients are likely to have excellent outcomes without adjuvant systemic therapies or which are at high risk for recurrence and might benefit from HER2 with or without an anthracycline, leading to overtreatment of some patients out of an abundance of caution, she said at the annual Miami Breast Cancer Conference, held by Physicians’ Education Resource.

In a video interview, Dr. Hurvitz discussed strategies under development for identifying and evaluating biomarkers and cardiac imaging studies that could help to identify patients at highest risk for long-term cardiotoxicity, as well as alternative therapeutic regimens that eliminate the need for anthracyclines.

Dr. Hurvitz disclosed grants/research support from Amgen, Bayer, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Pfizer, Roche, Biomarin, Merrimack, OBI Pharma, Puma Biotechnology, Dignitana, Medivation, Lilly and Novartis, and travel reimbursement from Lilly, Novartis, and OBI Pharma.

Recommended Reading

Guideline recommends 2-mm negative margins for DCIS
MDedge Surgery
ASCO updates postmastectomy radiotherapy guideline
MDedge Surgery
Boost dose pays off long term after surgery, WBRT for DCIS
MDedge Surgery
Partial-breast irradiation alternative to mastectomy following recurrence
MDedge Surgery
Halogenated anesthetic linked to less chronic postop mastectomy pain
MDedge Surgery
Younger age, greater anxiety, affect pain after breast reconstruction
MDedge Surgery
SLND after neoadjuvant chemo is feasible, but more study needed
MDedge Surgery
Counsel women against unnecessary prophylactic mastectomies
MDedge Surgery
Survival better with breast-conserving therapy for early cancers
MDedge Surgery
VIDEO: Breast surgeons can and do provide genetic counseling to cancer patients
MDedge Surgery